Fellowships, Grants, & Awards by unknown
A 476 VOLUME 113 | NUMBER 7 | July 2005 • Environmental Health Perspectives
Announcements Fellowships, Grants, & Awards
Stem Cells and Cancer
The clonal nature of most malignant tumors is well
established. Experiments spanning several decades
have shown, however, that as many as one million
murine or human tumor cells are required to trans-
plant a new tumor from an existing one. Two theories
have been developed to account for the observation
that apparently not every tumor cell is a tumor initiat-
ing cell (T-IC). The stochastic theory predicts that
every tumor cell can form an entirely new tumor;
however, entry into the cell cycle is a stochastic event
with low probability. Alternatively, tumor cells may
exist in a hierarchical state in which only a small num-
ber of cells possess tumor initiating potential. If the
stochastic model is correct, then tumor cells are bio-
logically homogeneous and genetic or epigenetic pro-
grams that allow for tumorigenesis are operative in the
majority of cells that comprise a tumor. The hierar-
chical model, however, predicts the tumor cells pos-
sess a functional heterogeneity and that quantitatively
the cells capable of tumorigenesis are a relatively
minor population among the bulk of tumor cells.
Recent data from both hematologic malignancies
and solid tumors have suggested that there are only
minor populations of cells in each malignancy that are
capable of tumor initiation. These T-ICs have the
functional properties of tumor stem cells. They appear
to be capable of asymmetric division and self renewal,
are only a minor faction among the bulk of more dif-
ferentiated cells in the tumor, and can reconstitute all
the cell types in the tumor of origin.
Currently, tumor stem cells have been isolated
and characterized in several hematologic malignancies
and some solid tumors. One of the first tumors in
which a stem cell was identified was acute myeloid
leukemia (AML). In this disease, the frequency of the
leukemic stem cell (LSC) was approximately 1 per
million AML blasts, establishing that not every AML
cell had T-IC capacity. A CD34 positive/CD38 neg-
ative cell fraction representing 0.1 to 1 percent of the
tumor cells possessed all the leukemia initiating activ-
ity in the NOD/SCID transplantation model. By
contrast, the major fraction of the CD34 positive/
CD38 positive cells and the majority of CD34 nega-
tive cells, which comprise most of the cells in the
tumor, could not initiate leukemia. A multiple
myeloma stem cell has also been characterized.
Multiple myeloma cell lines and primary patient
derived cells express the cell surface marker syndecan-
1 (CD138). A population of cells representing less
than 5 percent of the cells in the bulk population of
multiple myeloma cells was found to be CD138 neg-
ative, and possessed in vitro clonogenic potential.
These cells also engrafted successfully into Non-obese
Diabetic/Severe Combined Immunodeficient
(NOD/SCID mice), whereas CD138 positive cells
did not engraft.
Recently, a mammary carcinoma stem cell has
been isolated from primary mammary carcinomas
using four cell surface markers (CD44; CD24; a
mammary tumor marker, and epithelial speciﬁc anti-
gen). The tumor initiating capacity of the cells was
again veriﬁed in an in vivo NOD/SCID engraftment
assay. The mammary tumor stem cells represented
only 2 percent of the unfractionated bulk tumor cells.
Finally, a putative brain tumor stem cell has also
been isolated. These cells appear to be between 0.3
to 25 percent of the cells in the brain tumors exam-
ined. They are positive for the neural stem cell
marker CD133 and have a marked capacity for self
renewal and differentiation. Transplantation of these
putative neural tumor stem cells into the forebrains
of NOD/SCID mice yields tumors phenotypically
resembling the tumors from which the stem cells
were isolated.
Isolation of tumor stem cells from a larger spec-
trum of solid tumors and characterization of markers
for such cells will be important in understanding
how general the role of tumor stem cells are in the
pathogenesis of cancer.
In addition to isolating and characterizing tumor
stem cells themselves, it is also important to identify
the genes and proteins that facilitate the self renewal
phenotype that characterize all stem cells. The pro-
teins involved in self renewal in embryonic and adult
stem cells appear to be subverted in tumorigenesis
to allow the tumor-initiating cells to maintain self
renewal capacity. Two families of proteins related to
self renewal, the polycomb gene Bmi-1 and the Wnt
signaling pathway proteins, have been related to the
maintenance of the tumor stem cell phenotype.
The polycomb genes have an essential role in
embryogenesis, regulation of the cell cycle, and lym-
phopoieisis. These genes are transcriptional repressors
that are essential for the silencing of other families of
genes. Deletion of polycomb gene Bmi-1 in mice
results in a progressive loss of all hematopoietic
lineages. This loss results from the inability of the
Bmi-1(-/-) stem cells to self renew. Introducing genes
known to produce AML into Bmi-1(-/-) hemato-
poeitic stem cells (fetal liver cells), induced AML
with normal kinetics; however, the Bmi-1(-/-)
leukemic stem cells from primary recipients were
unable to produce AML in secondary recipients.
These results demonstrate that Bmi-1 is also required
for self renewal of leukemic stem cells in the murine
AML model.
Another group of genes involved in self renewal
are those involved in the Wnt signal transduction
cascade. The Wnt protein binds to a receptor called
Frizzled and activates cell fate decisions during tissue
development. Inhibitors of Wnt signaling produce
inhibition of hematopoietic stem cell growth in vitro
and reduce hematopoietic reconstitution in vitro.
Activation of Wnt signaling in hematopoeitic stem
cells leads to increased expression of Hox B4 and
Notch-1 genes previously implicated in self renewal
of hematopoietic stem cells. The Wnt signaling path-
way is involved in both hematopoietic malignancy
and colon carcinoma. Although the Wnt ligands
themselves are only rarely involved in tumorigenesis,
mutations mimicking Wnt receptor (Frizzled) activa-
tion induce a set of genes associated with repression
of differentiation and potentiation of self-renewal. In
general, these mutations involve Wnt signal transduc-
tion proteins including the activation of beta-catenin
and inactivation of the (APC) adenomatosis poly-
posis coli protein. In myeloid leukemia, nonphos-
phorylated beta-catenin accumulates in granulocyte-
macrophage progenitors as they progress toward
leukemia. These normally more committed progeni-
tors can thus acquire self-renewal properties. A simi-
lar accumulation of unphosphorylated beta-catenin
has also been observed in multiple myeloma cells.
In colon cancer, the APC gene is mutated early in
the development of about 90 percent of the colon
carcinomas. Similarity in gene expression patterns
between populations of colon cancer cells and colon
epithelial stem cells has also been observed by DNA
microarray analysis. It is possible that mutations in
the Wnt signaling pathway maintain the program of
stem cell genes in the transcriptionally active state.
Additional research on the important genes and
proteins that function to maintain the stem cell phe-
notype could contribute to increasing the number of
specific targets for which cancer therapeutic agents
can be designed.
Recent studies of Helicobacter infection in mice
have suggested that bone marrow hematopoietic
stem cells can contribute to repopulating the gastric
mucosal epithelium. These cells can progress, with
time, to metaplasia, dysplasia, and cancer. The pos-
sibility of stable fusion between the bone marrow
derived cells and the gastric mucosa was eliminated,
suggesting the possibility of transdifferentiation of
hematopoietic stem cells. Research aimed at estab-
lishing whether or not stem cells have the capacity to
transdifferentiate is also encouraged.
This funding opportunity is intended to pro-
mote research on all aspects of tumor stem cell biol-
ogy, and on the genes and proteins responsible for
the tumor stem cell phenotype. Research studies on
the characterization of tumor stem cells from the
broad spectrum of solid and liquid tumors not
already examined, on markers potentially shared by
tumor stem cells and normal stem cells, and on the
biochemical and molecular regulation of normal and
tumor stem cell function are encouraged. Such
research can and should include research on in vivo
assays for the functional identiﬁcation of such cells.
Studies of the genes regulating self renewal, and
studies of regulation of stem cell division by the stem
cell niche and/or microenvironment are also encour-
aged. Investigators working on the cell and molecu-
lar biology of embryonic stem cells, adult stem cells,
and tumor stem cells are encouraged to apply for
support under this funding opportunity. The follow-
ing questions illustrate areas of high interest, but
other relevant innovative projects are also encour-
aged: 1) What governs the proliferation rate of nor-
mal and tumor stem cells? 2) Can oncogenes and
their associated mutations affect asymmetric versus
symmetric divisions in stem cells? 3) Stem cell quies-
cence versus growth must ultimately be understood
in terms of progression through the cell cycle.
Which stem cell-specific genes alter the cell cycle
pathway proteins? 4) Do tumor stromal cells con-
stitute a unique tumor stem cell niche? Does the
tumor stromal niche act as a constituent of a feed-
back mechanism with tumor stem cells to control
their growth? 5) Are the phenotypes of invasion and
metastasis uniquely connected to the tumor stem cell
phenotype? 6) Are normal resident adult tissue stem
cells a special target for carcinogenic insults? 7) Can
new and/or better markers and assays for the isola-
tion and enrichment of tumor stem cells be devel-
oped? 8) Can new and/or better in vivo functional
assays to identify tumor initiating cells (e.g., engraft-
ment of leukemic stem cells into immunodeficient
NOD/SCID mice) be developed? 9) How do
changes to stem cells or their environment due to
aging affect formation of tumor stem cells or alter
their properties?
This funding opportunity will use the R01 and
R21 award mechanisms. As an applicant, you will be
solely responsible for planning, directing, and exe-
cuting the proposed project.
This funding opportunity uses just-in-time con-
cepts. It also uses the modular as well as the non-
modular budget formats (see http://grants.nih.gov/
grants/funding/modular/modular.htm). Specifically,
if you are submitting an application with direct costs
in each year of $250,000 or less, use the modularFellowships, Grants, & Awards
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budget format described in the PHS 398 application
instructions. Otherwise, follow the instructions for
non-modular research grant applications.
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants
must use the currently approved version of the PHS
398. For further assistance, contact GrantsInfo at
301-435-0714, (telecommunications for the bearing
impared: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) num-
ber as the universal identifier when applying for
Federal grants or cooperative agreements. The D&B
number can be obtained by calling 866-705-5711 or
through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of
the face page of the PHS 398 form. The complete
version of this PA is available at http://grants/guide/
pa-ﬁles/PAR-05-086.html.
Contact: R. Allan Mufson, Cancer Immunology
Hematology Branch, Division of Cancer Biology,
National Cancer Institute, 6130 Executive Blvd,
EPN Rm 5062, Bethesda, MD 20892 USA,
Rockville, MD 20852 USA (for express/courier ser-
vice) 301-496-7815, Fax: 301-480-2844, E-mail:
am214t@nih.gov; Jill Carrington, Systems Branch,
Musculoskeletal Biology, Biology of Aging Program,
National Institute on Aging, National Institutes of
Health, 7201 Wisconsin Ave, Suite 2C231, MSC
9205, Bethesda, MD 20892 USA, 301-496-6402,
fax: 301-402-0010, e-mail: carringtonj@nia.nih.gov.
Reference: PA No. PA-05-086
Secondary Analyses in Obesity, Diabetes,
Digestive and Kidney Diseases
The specific objectives of this announcement on
Secondary Analyses In Obesity, Diabetes, Digestive
And Kidney Diseases are to support the following:
(a) research on secondary analyses of data related
to the epidemiology of disease areas of NIDDK;
(b) preliminary projects using secondary analysis that
could lead to subsequent applications for individual
research awards; (c) rapid analyses of new databases
and experimental modules to inform the design and
content of future studies; (d) the archiving of data
sets to be made publicly available for research pur-
poses related to disease areas of NIDDK, including
both epidemiological studies and multi-center clinical
trials.
Research that employs analytic techniques that
demonstrate or promote methodological advances in
patient-oriented and epidemiologic research is also
of interest. International comparative analyses are
encouraged. Applications that are innovative and
high risk with the likelihood for high impact would
be especially encouraged.
Patient-oriented and epidemiologic research pro-
jects, particularly multicenter projects, typically gen-
erate data with potential utility beyond the specific
hypotheses and questions for which they were
designed. Often data are not fully analyzed, especially
when unexpected research questions emerge after the
end of the project's funding period. Analyzing such
existing data sets can therefore provide a cost-effective
means to test speciﬁc hypotheses that have not been
adequately examined. The further analysis of existing
research data may also be prompted by a need to con-
firm new findings or to aid in the development of
new research questions.
Applicants may conduct secondary analyses
using data from a variety of sources. These would
include investigator-initiated research activities, coop-
erative agreements, and contracts or from other pub-
lic or private sources. Sources may be large, nationally
representative data sets such as those of the National
Center for Health Statistics or smaller, regional or
locally based data sets. Also appropriate for secondary
analyses are relevant cross-sectional and longitudinal
survey data collected by federal, state, and local gov-
ernment agencies. Secondary data analyses of these
data may serve as an economical alternative to expen-
sive and time-consuming new data collection pro-
jects. Applicants may also secure access to other data
sets that may or may not be in the public domain,
such as those collected under research grant funds,
sponsored by private entities, or originally collected
for purposes other than research, such as health care
administrative data sets.
In addition to the examination of specific
research hypotheses, existing data sets may also be
used to cross-validate exploratory analyses in ongo-
ing studies, to test complex statistical models, and in
special circumstances to provide comparison groups
for experimental studies. Moreover, secondary analy-
sis is appropriate for many types of data, including
qualitative information, and may also cover the inte-
gration of quantitative and qualitative data.
NIDDK has established a repository for the
archiving of data sets, as well as genetics and tissues
from NIDDK sponsored clinical trials and epidemi-
ological studies (http://pubnts06.rti.org/niddk/
home.do). Applicants are encouraged to consider the
research opportunities available in this NIDDK
resource.
A major interest of NIDDK is supporting sec-
ondary data analyses in the causes, burden, natural
history, and treatment and medical care of overweight
and obesity, including analyses of behavioral/environ-
mental factors that may be predictive of long term
weight maintenance or prevention of weight gain.
Other speciﬁc subject areas are restricted to those on
which NIDDK conducts research, which include dia-
betes and endocrine and metabolic diseases; digestive
diseases and nutritional disorders, including eating
disorders; and kidney, urological, and hematological
diseases. All data analyses must concern patient-ori-
ented or epidemiologic research designed to elucidate
the etiology, incidence, prevalence, natural history,
pathophysiology, or response to therapy of the above-
mentioned disorders.
This program announcement addresses several
areas considered to be high priority for liver disease
research as delineated in the recently published
Trans-NIH Action Plan for Liver Disease Research
(http://liverplan.niddk.nih.gov), specifically in the
areas of fatty liver disease, viral hepatitis, drug- and
toxicant-induced liver disease, autoimmune liver dis-
ease, pediatric liver disease, liver transplantation,
complications of liver disease, and gallbladder and
biliary disease.
This mechanism can also be used for the merging
of secondary data sets with other data sets. For exam-
ple, if allowed by informed consent, databases could
be matched with hospital data sets or vital statistics to
assess longer-term morbidity and/or mortality of
patient groups. Meta-analysis, in which results from
multiple studies may be compared or combined, is
encouraged only if patient level data from the original
studies are combined.
Support for the creation of publicly archived
data sets involved in secondary analyses would be for
information that could be applied to the subject
areas of interest. Plans for archiving must include
adequate dataset documentation and explanation so
that it can be used by researchers not associated with
the original study. Provision for easy accessibility of
archived datasets is required.
Up to 25% of the direct costs of the grant may
be spent on acquiring new information that would be
incorporated into the database and would signiﬁcantly
strengthen the analysis. Such information may, for
example, be derived from laboratory testing of stored
specimens or comparisons of a measurement against a
criterion standard to validate the measurement in the
database. Conversion of data from paper records to
electronic form would also be considered up to the
25% limit. Obtaining such new information must
serve the purpose of the secondary data analysis and
should not be considered for any other reason.
This funding opportunity will use the NIH
Exploratory/Developmental (R21) award mecha-
nism. As an applicant, you will be solely responsible
for planning, directing, and executing the proposed
project.
This funding opportunity uses just-in-time
concepts. It also uses the modular budget format
described in the PHS 398 application instructions
(see http://grants.nih.gov/grants/funding/modular/
modular.htm).
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants
must use the currently approved version of the PHS
398. For further assistance contact GrantsInfo at
301-435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) num-
ber as the universal identifier when applying for
Federal grants or cooperative agreements. The D&B
number can be obtained by calling 866-705-5711 or
through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of
the face page of the PHS 398 form. The complete
version of this PA is available at http://grants.nih.
gov/grants/guide/pa-ﬁles/PA-05-091.html.
Contact: James E. Everhart, Epidemiology and
Clinical Trials Branch, Division of Digestive Diseases
and Nutrition, National Institute of Diabetes and
Digestive and Kidney Diseases, 6707 Democracy
Blvd, Rm 655, Bethesda MD 20892-5450 USA, 301-
594-8878, fax: 301-480-8300, e-mail: je17g@nih.gov;
Catherine C. Cowie, Type 1 Diabetes Clinical Trials
Program, Division of Diabetes, Endocrinology, and
Metabolism, National Institute of Diabetes and
Digestive and Kidney Diseases, 6707 Democracy
Blvd, Rm 691, Bethesda, MD 20892-5460 USA, 301-
594-8804, fax: 301-480-3503, e-mail: cc68v@nih.gov;
Paul W. Eggers, Epidemiology and U.S. Renal
Data System, Division of Kidney, Urologic, and
Hematologic Diseases, National Institute of Diabetes
and Digestive and Kidney Diseases, 6707 Democracy
Blvd, Rm 615, Bethesda, MD 20892-5458 USA, 301
594-8305, fax: 301-480-3510, e-mail: pe39h@
nih.gov. Reference: PA No. PA-05-091